| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
iTeos Therapeutics Inc (NASDAQ: ITOS)
ITOS Technical Analysis
5
| As on 9th Jun 2023 ITOS STOCK Price closed @ 14.24 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 27.21 & Strong Sell for SHORT-TERM with Stoploss of 38.79 we also expect STOCK to react on Following IMPORTANT LEVELS. |
ITOSSTOCK Price
| Open | 15.19 | Change | Price | % |
| High | 15.20 | 1 Day | -0.87 | -5.76 |
| Low | 14.15 | 1 Week | -3.81 | -21.11 |
| Close | 14.24 | 1 Month | 0.79 | 5.87 |
| Volume | 201625 | 1 Year | -28.96 | -67.04 |
| 52 Week High 47.86 | 52 Week Low 12.93 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| ITOS Daily Charts |
ITOS Intraday Charts |
Whats New @ Bazaartrend |
ITOS Free Analysis |
|
|
ITOS Important Levels Intraday
| RESISTANCE | 16.26 |
| RESISTANCE | 15.61 |
| RESISTANCE | 15.21 |
| RESISTANCE | 14.81 |
| SUPPORT | 13.67 |
| SUPPORT | 13.27 |
| SUPPORT | 12.87 |
| SUPPORT | 12.22 |
ITOS Forecast May 2024
| 4th UP Forecast | 35.23 |
| 3rd UP Forecast | 28.5 |
| 2nd UP Forecast | 24.34 |
| 1st UP Forecast | 20.18 |
| 1st DOWN Forecast | 8.3 |
| 2nd DOWN Forecast | 4.14 |
| 3rd DOWN Forecast | -0.02 |
| 4th DOWN Forecast | -6.75 |
ITOS Weekly Forecast
| 4th UP Forecast | 23.99 |
| 3rd UP Forecast | 20.86 |
| 2nd UP Forecast | 18.93 |
| 1st UP Forecast | 17.00 |
| 1st DOWN Forecast | 11.48 |
| 2nd DOWN Forecast | 9.55 |
| 3rd DOWN Forecast | 7.62 |
| 4th DOWN Forecast | 4.49 |
ITOS Forecast2024
| 4th UP Forecast | 90.9 |
| 3rd UP Forecast | 66.31 |
| 2nd UP Forecast | 51.12 |
| 1st UP Forecast | 35.92 |
| 1st DOWN Forecast | -7.44 |
| 2nd DOWN Forecast | -22.64 |
| 3rd DOWN Forecast | -37.83 |
| 4th DOWN Forecast | -62.42 |
iTeos Therapeutics Inc ( NASDAQ USA Symbol : ITOS )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
ITOS Business Profile
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2a receptor that is an open-label Phase 1/2a clinical trial in adult patients; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2a clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Cambridge, Massachusetts. Address: 139 Main Street, Cambridge, MA, United States, 02142
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service